Sphere formation reverses the metastatic and cancer stem cell phenotype of the murine mammary tumour 4T1, independently of the putative cancer stem cell marker Sca-1

Cancer Letters

Volumn 323, Issue 1, 2012, Pages 20-28

  Matilainen, Heli ^a   Yu, Xiao Wen ^a,b   Tang, Ching Wen ^a   Berridge, Michael V ^a   McConnell, Melanie J ^a  

^a MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

4T1; Metastasis; Sca1; TGF signalling; Tumour spheres

Indexed keywords

ATAXIN 1; CELL MARKER; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER STEM CELL; CELL DIFFERENTIATION; CELL POPULATION; CELL RENEWAL; CELL SHAPE; CELL TRANSFORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION REGULATION; IN VITRO STUDY; IN VIVO STUDY; LONG TERM EXPOSURE; LUNG METASTASIS; MOUSE; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR VOLUME; UPREGULATION;

ANIMALS; ANTIGENS, LY; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; FLOW CYTOMETRY; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; NEOPLASTIC STEM CELLS; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

MURINAE;

EID: 84861825364     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.03.028     Document Type: Article

References (44)

1. Bomken S., Fiser K., Heidenreich O., Vormoor J. Understanding the cancer stem cell. Br. J. Cancer 2010, 103:439-445.
2. Kashyap V., Rezende N.C., Scotland K.B., Shaffer S.M., Persson J.L., Gudas L.J., Mongan N.P. Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. Stem Cells Dev. 2009, 18:1093-1108.
3. Leis O., Eguiara A., Lopez-Arribillaga E., Alberdi M.J., Hernandez-Garcia S., Elorriaga K., Pandiella A., Rezola R., Martin A.G. Sox2 expression in breast tumours and activation in breast cancer stem cells. Oncogene 2011.
4. Velasco-Velazquez M.A., Popov V.M., Lisanti M.P., Pestell R.G. The role of breast cancer stem cells in metastasis and therapeutic implications. Am. J. Pathol. 2011, 179:2-11.
5. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., Minden M., Paterson B., Caligiuri M.A., Dick J.E. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
6. Nakshatri H., Srour E.F., Badve S. Breast cancer stem cells and intrinsic subtypes: controversies rage on. Curr. Stem Cell Res. Ther. 2009, 4:50-60.
7. Idowu M.O., Kmieciak M., Dumur C., Burton R.S., Grimes M.M., Powers C.N., Manjili M.H. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum. Pathol. 2011.
8. Wang Z., Shi Q., Gu Y., Shen Y., Sun M., Deng M., Zhang H., Fang J., Zhang S., Xie F. Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1alpha in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol. Res. Pract. 2011, 207:505-513.
9. Ricardo S., Vieira A.F., Gerhard R., Leitao D., Pinto R., Cameselle-Teijeiro J.F., Milanezi F., Schmitt F., Paredes J. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. J. Clin. Pathol. 2011, 64:937-946.
10. Wang K.H., Kao A.P., Chang C.C., Lee J.N., Hou M.F., Long C.Y., Chen H.S., Tsai E.M. Increasing CD44+/CD24(-) tumor stem cells, and upregulation of COX-2 and HDAC6, as major functions of HER2 in breast tumorigenesis. Mol Cancer 2010, 9:288.
11. Kim H.J., Kim M.J., Ahn S.H., Son B.H., Kim S.B., Ahn J.H., Noh W.C., Gong G. Different prognostic significance of CD24 and CD44 expression in breast cancer according to hormone receptor status. Breast 2011, 20:78-85.
12. Huang M., Li Y., Zhang H., Nan F. Breast cancer stromal fibroblasts promote the generation of CD44+CD24- cells through SDF-1/CXCR4 interaction. J. Exp. Clin. Cancer Res. 2010, 29:80.
13. Blick T., Hugo H., Widodo E., Waltham M., Pinto C., Mani S.A., Weinberg R.A., Neve R.M., Lenburg M.E., Thompson E.W. Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44(hi/)CD24 (lo/-) stem cell phenotype in human breast cancer. J. Mammary Gland Biol. Neoplasia 2010, 15:235-252.
14. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
15. Grange C., Lanzardo S., Cavallo F., Camussi G., Bussolati B. Sca-1 identifies the tumor-initiating cells in mammary tumors of BALB-neuT transgenic mice. Neoplasia 2008, 10:1433-1443.
16. Classon B.J., Coverdale L. Mouse stem cell antigen Sca-2 is a member of the Ly-6 family of cell surface proteins. Proc. Natl. Acad. Sci. USA 1994, 91:5296-5300.
17. Welm B.E., Tepera S.B., Venezia T., Graubert T.A., Rosen J.M., Goodell M.A. Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population. Dev. Biol. 2002, 245:42-56.
18. Upadhyay G., Yin Y., Yuan H., Li X., Derynck R., Glazer R.I. Stem cell antigen-1 enhances tumorigenicity by disruption of growth differentiation factor-10 (GDF10)-dependent TGF-beta signaling. Proc. Natl. Acad. Sci. USA 2011, 108:7820-7825.
19. Bradfute S.B., Graubert T.A., Goodell M.A. Roles of Sca-1 in hematopoietic stem/progenitor cell function. Exp. Hematol. 2005, 33:836-843.
20. Hirschhaeuser F., Menne H., Dittfeld C., West J., Mueller-Klieser W., Kunz-Schughart L.A. Multicellular tumor spheroids: an underestimated tool is catching up again. J. Biotechnol. 2010, 148:3-15.
21. Ward R.J., Dirks P.B. Cancer stem cells: at the headwaters of tumor development. Annu. Rev. Pathol. 2007, 2:175-189.
22. Pulaski B.A., Ostrand-Rosenberg S. Mouse 4T1 Breast Tumor Model 2001, John Wiley & Sons, Inc.
23. Kim R.J., Kim S.R., Roh K.J., Park S.B., Park J.R., Kang K.S., Kong G., Tang B., Yang Y.A., Kohn E.A., Wakefield L.M., Nam J.S. Ras activation contributes to the maintenance and expansion of Sca-1pos cells in a mouse model of breast cancer. Cancer Lett. 2010, 287:172-181.
24. Glazer R.I., Wang X., Yuan H., Yin Y. Mammary stem and progenitor cell regulation. Cancer Biomark. 2007, 3:171-181.
25. Staud F., Pavek P. Breast cancer resistance protein (BCRP/ABCG2). Int. J. Biochem. Cell Biol. 2005, 37:720-725.
26. Morel A.P., Lievre M., Thomas C., Hinkal G., Ansieau S., Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 2008, 3:e2888.
27. Santisteban M., Reiman J.M., Asiedu M.K., Behrens M.D., Nassar A., Kalli K.R., Haluska P., Ingle J.N., Hartmann L.C., Manjili M.H., Radisky D.C., Ferrone S., Knutson K.L. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res. 2009, 69:2887-2895.
28. Li Y., Welm B., Podsypanina K., Huang S., Chamorro M., Zhang X., Rowlands T., Egeblad M., Cowin P., Werb Z., Tan L.K., Rosen J.M., Varmus H.E. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc. Natl. Acad. Sci. USA 2003, 100:15853-15858.
29. Pulaski B.A., Ostrand-Rosenberg S. Mouse 4T1 breast tumor model. Curr. Protoc. Immunol. Chapter 2001, 20. (Unit 20 22).
30. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
31. Broadley K.W., Hunn M.K., Farrand K.J., Price K.M., Grasso C., Miller R.J., Hermans I.F., McConnell M.J. Side population is not necessary or sufficient for a cancer stem cell phenotype in glioblastoma multiforme. Stem. Cells 2011, 29:452-461.
32. Cooke S.L., Temple J., Macarthur S., Zahra M.A., Tan L.T., Crawford R.A., Ng C.K., Jimenez-Linan M., Sala E., Brenton J.D. Intra-tumour genetic heterogeneity and poor chemoradiotherapy response in cervical cancer. Br. J. Cancer 2011, 104:361-368.
33. Massague J. TGFbeta in Cancer. Cell 2008, 134:215-230.
34. Holmes C., Stanford W.L. Concise review: stem cell antigen-1: expression, function, and enigma. Stem Cells 2007, 25:1339-1347.
35. Ikushima H., Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat. Rev. Cancer 2010, 10:415-424.
36. Muraoka R.S., Dumont N., Ritter C.A., Dugger T.C., Brantley D.M., Chen J., Easterly E., Roebuck L.R., Ryan S., Gotwals P.J., Koteliansky V., Arteaga C.L. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 2002, 109:1551-1559.
37. Witz I.P. Differential expression of genes by tumor cells of a low or a high malignancy phenotype: the case of murine and human Ly-6 proteins. J. Cell. Biochem. Suppl. 2000, 34:61-66.
38. Yuan H., Upadhyay G., Yin Y., Kopelovich L., Glazer R.I. Stem cell antigen-1 deficiency enhances the chemopreventive effect of peroxisome proliferator-activated receptorgamma activation. Cancer Prev. Res. (Phila.) 2012, 5:51-60.
39. Batts T.D., Machado H.L., Zhang Y., Creighton C.J., Li Y., Rosen J.M. Stem cell antigen-1 (sca-1) regulates mammary tumor development and cell migration. PLoS ONE 2011, 6:e27841.
40. Roarty K., Baxley S.E., Crowley M.R., Frost A.R., Serra R. Loss of TGF-beta or Wnt5a results in an increase in Wnt/beta-catenin activity and redirects mammary tumour phenotype. Breast Cancer Res. 2009, 11:R19.
41. Wang Y., Yu Y., Tsuyada A., Ren X., Wu X., Stubblefield K., Rankin-Gee E.K., Wang S.E. Transforming growth factor-beta regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene 2011, 30:1470-1480.
42. Barrett L.E., Granot Z., Coker C., Iavarone A., Hambardzumyan D., Holland E.C., Nam H.S., Benezra R. Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. Cancer Cell 2012, 21:11-24.
43. Alison M.R., Guppy N.J., Lim S.M., Nicholson L.J. Finding cancer stem cells: are aldehyde dehydrogenases fit for purpose?. J. Pathol. 2010, 222:335-344.
44. Moore N., Lyle S. Quiescent slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance. J. Oncol. 2011, 2011.